T1	Participants 524 774	Consecutive consenting patients from one center in a multicenter trial that compared 6 months of low molecular weight heparin with oral anticoagulant therapy were treated with therapeutic doses of dalteparin (200 IU per kilogram) subcutaneously daily
T2	Participants 874 947	Patients were followed for bleeding and recurrent venous thromboembolism.
T3	Participants 377 522	This study is a prospective assessment of anti-Xa levels in patients on long-term therapy for acute venous thromboembolism who have active cancer
